# Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients

> **NCT07709013** · PHASE2 · RECRUITING · sponsor: **Tata Memorial Centre** · enrollment: 22 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Leflunomide 20 mg

## Key facts

- **NCT ID:** NCT07709013
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709013, "Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07709013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*